<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2815">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04834115</url>
  </required_header>
  <id_info>
    <org_study_id>PINV20-387</org_study_id>
    <nct_id>NCT04834115</nct_id>
  </id_info>
  <brief_title>Efficacy of Ivermectin in Outpatients With Non-severe COVID-19</brief_title>
  <official_title>Efficacy of Ivermectin in Outpatients With Non-severe COVID-19: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Nacional de Asunción</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Consejo Nacional de Ciencias y Tecnologia, Paraguay</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministerio de Salud Pública y Bienestar Social, Paraguay</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro de información y recursos para el desarrollo, Paraguay</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro para el Desarrollo de la Investigación Científica, CEDIC, Paraguay</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Desarrollo, Paraguay</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad Nacional de Asunción</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial to evaluate the efficacy of ivermectin in reducing the&#xD;
      risk of progression to severe disease and hospitalizations in COVID-19 patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized controlled trial to evaluate the efficacy of ivermectin in COVID-19&#xD;
      outpatients reducing the risk of progression to severe disease.&#xD;
&#xD;
      Patients with COVID-19 infection are randomized to receive a single dose of 200mcg/kg of&#xD;
      ivermectin or a placebo.&#xD;
&#xD;
      The randomization code is generated by the trial statistician. The allocation is made after&#xD;
      fulfilment of both inclusion and exclusion criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 17, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a double blind, randomized controlled trial with two parallel groups that evaluates the efficacy of ivermectin in reducing hospitalization in outpatients with COVID-19.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Triple (Participant, Investigator, Outcomes Assessor)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with hospitalization criteria</measure>
    <time_frame>30 days</time_frame>
    <description>Proportion of patients with hospitalization criteria at day 30</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with COVID-19 signs and symptoms</measure>
    <time_frame>14 days</time_frame>
    <description>Proportion of patients with COVID-19 signs and symptoms up to day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of cohabitants who had COVID-19 after the index case</measure>
    <time_frame>30 days</time_frame>
    <description>Proportion of cohabitants who had COVID-19 after the index case up to day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug-related adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>Proportion of patients with ivermectin adverse events up to day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of IgG for SARS-CoV-2</measure>
    <time_frame>30-60 days</time_frame>
    <description>Quantitative levels of IgG for SARS-CoV-2 measured by ELISA immunoassay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Covid19</condition>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>Ivermectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ivermectin 200mcg/kg single dose, maximum dose 18mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inactive medication tablets indistinguishable from ivermectin tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin Tablets</intervention_name>
    <description>Oral ivermectin at a one time dose</description>
    <arm_group_label>Ivermectin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral placebo at a one time dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Positive diagnostic RT-qPCR or antigen test for SARS-CoV-2&#xD;
&#xD;
          -  Symptomatic patients with up to 8 days from the onset of symptoms, and asymptomatic&#xD;
             cases with up to 5 days of positive test for SARS-CoV-2.&#xD;
&#xD;
          -  Patients who agree to participate in the study by signing the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with severity criteria defined in the Coronavirus Disease Epidemiological and&#xD;
             Laboratory Surveillance Guide (Version 3/11/2020)&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Women of childbearing age and without commitment to use contraceptive methods during&#xD;
             the study time.&#xD;
&#xD;
          -  Inability to complete the study&#xD;
&#xD;
          -  Current treatment with drugs known to interact with ivermectin&#xD;
&#xD;
          -  Known intolerance to ivermectin, its derivate or any of its excipients.&#xD;
&#xD;
          -  Patients with known Child-Pugh C liver disease&#xD;
&#xD;
          -  Patients with prior ivermectin consumption in the 10 days prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gabriela Avila, MD, MSc, PhD</last_name>
    <phone>+59521683930</phone>
    <phone_ext>324</phone_ext>
    <email>mavila@med.una.py</email>
  </overall_contact>
  <location>
    <facility>
      <name>Facultad de Ciencias Médicas - Universidad Nacional de Asunción</name>
      <address>
        <city>Asunción</city>
        <zip>111421</zip>
        <country>Paraguay</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela Avila, MD, MSc, PhD</last_name>
      <phone>+59521683930</phone>
      <email>mavila@med.una.py</email>
    </contact>
  </location>
  <location_countries>
    <country>Paraguay</country>
  </location_countries>
  <link>
    <url>https://datos.conacyt.gov.py/proyectos/pdf/3449</url>
    <description>National Council of Science and Technology, Paraguay</description>
  </link>
  <link>
    <url>http://pi.net.py</url>
    <description>Project Official Web Site</description>
  </link>
  <reference>
    <citation>López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, Díazgranados JA, Oñate JM, Chavarriaga H, Herrera S, Parra B, Libreros G, Jaramillo R, Avendaño AC, Toro DF, Torres M, Lesmes MC, Rios CA, Caicedo I. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. JAMA. 2021 Mar 4. doi: 10.1001/jama.2021.3071. [Epub ahead of print]</citation>
    <PMID>33662102</PMID>
  </reference>
  <reference>
    <citation>Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.</citation>
    <PMID>32251768</PMID>
  </reference>
  <reference>
    <citation>Chaccour C, Ruiz-Castillo P, Richardson MA, Moncunill G, Casellas A, Carmona-Torre F, Giráldez M, Mota JS, Yuste JR, Azanza JR, Fernández M, Reina G, Dobaño C, Brew J, Sadaba B, Hammann F, Rabinovich R. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial. Trials. 2020 Jun 8;21(1):498. doi: 10.1186/s13063-020-04421-z.</citation>
    <PMID>32513289</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 28, 2021</study_first_submitted>
  <study_first_submitted_qc>April 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>April 4, 2021</last_update_submitted>
  <last_update_submitted_qc>April 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ivermectin</keyword>
  <keyword>Communicable Diseases</keyword>
  <keyword>Respiratory Tract Infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The investigators will publish the results to compare data with other studies with ivermectin and SARS-CoV-2 infection.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

